argenex SE

ARGX Healthcare Biotechnology

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

819.14 27.13 −3.21%
Market cap
$53.2B
P/E
29.6×
Fwd P/E
32.4×
Dividend yield
—
F-score
5/9
Altman Z
24.36
Beneish M
−1.51
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 — 5 —

+8 more TTM periods

ROE
27.07% 0.00% 22.63% 0.00%
ROA
23.15% 0.00% 19.54% 0.00%
ROIC
20.71% 0.00% 17.19% 0.00%
Return on Tangible Assets
26.22% 0.00% 22.96% 0.00%
Average Days of Receivables
132.94 0.00 142.37 0.00
Free Cash Flow per Share
22.12 0.00 9.60 0.00
Free Cash Flow
1,378.46 — 588.50 —
Other line items

Show all line items

Columns are period end dates